TEVA - Teva Pharma Industries Ltd ADR - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TEVA is currently covered by 9 analysts with an average price target of $22.25. This is a potential upside of $4.18 (23.13%) from yesterday's end of day stock price of $18.07.

Teva Pharma Industries Ltd ADR's activity chart (see below) currently has 329 price targets and 291 ratings on display. The stock rating distribution of TEVA is 79.41% BUY, 17.65% HOLD and 2.94% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 60.69% with an average time for these price targets to be met of 308.83 days.

Highest price target for TEVA is $30, Lowest price target is $18, average price target is $22.57.

Most recent stock forecast was given by JASON GERBERRY from BAML on 06-Mar-2025.

Split History since 2000:

7/1/04 2 for 1

12/6/02 2 for 1

2/23/00 2 for 1

Best performing analysts who are covering TEVA - Teva Pharma Industries Ltd ADR:

Sumant Kulkarni Elliot Wilbur Ami Fadia Timothy Chiang Gregg Gilbert Randall Stanicky Liav Abraham David Maris Esther Rajavelu Jami Rubin

Currently out of the existing stock ratings of TEVA, 27 are a BUY (79.41%), 6 are a HOLD (17.65%), 1 are a SELL (2.94%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jason Gerberry (BAML)

Buy

$20

$3.81 (23.53%)

$21

2 months 3 days ago
(06-Mar-2025)

10/14 (71.43%)

$4.1 (25.79%)

148

Please subscribe to see the analyst performance score

Balaji Prasad (BARCLAYS)

Buy

$26

$9.81 (60.59%)

$28

3 months 9 days ago
(30-Jan-2025)

10/13 (76.92%)

$8.16 (45.74%)

335

Please subscribe to see the analyst performance score

Ashwani Verma (UBS)

Buy

$30

$13.81 (85.30%)

$26

3 months 16 days ago
(23-Jan-2025)

5/8 (62.5%)

$8.21 (37.68%)

Please subscribe to see the analyst performance score

David Amsellem (PIPER SANDLER)

Buy

$30

$13.81 (85.30%)

$20

3 months 22 days ago
(17-Jan-2025)

11/16 (68.75%)

$8.08 (36.86%)

152

Please subscribe to see the analyst performance score

Chris Schott (JPMORGAN)

Hold

$18

$1.81 (11.18%)

$11

6 months 18 days ago
(21-Oct-2024)

4/7 (57.14%)

$-0.18 (-0.99%)

181

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is TEVA (Teva Pharma Industries Ltd ADR) average time for price targets to be met?

On average it took 308.83 days on average for the stock forecasts to be realized with a an average price target met ratio 60.69

Which analyst has the current highest performing score on TEVA (Teva Pharma Industries Ltd ADR) with a proven track record?

SUMANT KULKARNI

Which analyst has the most public recommendations on TEVA (Teva Pharma Industries Ltd ADR)?

Sumant Kulkarni works at CANACCORD and has 9 price targets and 10 ratings on TEVA

Which analyst is the currently most bullish on TEVA (Teva Pharma Industries Ltd ADR)?

Sumant Kulkarni with highest potential upside - $33.88

Which analyst is the currently most reserved on TEVA (Teva Pharma Industries Ltd ADR)?

David Risinger with lowest potential downside - -$7.19

Teva Pharma Industries Ltd ADR in the News

Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Larry Robbins’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other stock picks with huge upside potential. Larry Robbins is an American hedge fund manager and philanthropist who founded Glenview...

Teva Pharmaceutical Industries (NYSE:TEVA) Settles Class-Action Lawsuit For US$2 Million

Teva Pharmaceutical Industries recently made headlines by agreeing to a $2.25 million settlement in a class-action lawsuit concerning Effexor XR®. This legal development, although not directly affecting the physical trading of its stock, played a part in the company’s 26% increase last month. This movement occurred within a generally positive market environment, where major indices...